XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

References

• YouJJSingerDEHowardPAAntithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e531Se575S22315271
   PubMed Web of Science ®Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke19912289839881866765
   PubMed Web of Science ®Google Scholar
• NieuwlaatROlssonSBLipGYGuideline-adherent anti-thrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial FibrillationAm Heart J200715361006101217540203
   PubMed Web of Science ®Google Scholar
• AnsellJHollowellJPengoVMartinez-BrotonsFCaroJDrouetLDescriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM)J Thromb Thrombolysis2007232839117221328
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaR2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• FurieKLGoldsteinLBAlbersGWOral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke AssociationStroke201243123442345322858728
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• Janssen PharmaceuticalsXarelto (rivaroxaban) [prescribing Information]2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202439s008lbl.pdfAccessed January 27, 2014
   Google Scholar
• Bayer PharmaXarelto (rivaroxaban) [summary of product characteristics]2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed April 23, 2014
   Google Scholar
• MueckWBeckaMKubitzaDVoithBZuehlsdorfMPopulation model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in healthy subjectsInt J Clin Pharmacol Ther200745633534417595891
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol2005611287388016328318
   PubMed Web of Science ®Google Scholar
• PerzbornERoehrigSStraubAKubitzaDMisselwitzFThe discovery and development of rivaroxaban, an oral, direct factor Xa inhibitorNat Rev Drug Discov2011101617521164526
   PubMed Web of Science ®Google Scholar
• BullerHRLensingAWPrinsMHA dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyBlood200811262242224718621928
   PubMed Web of Science ®Google Scholar
• AgnelliGGallusAGoldhaberSZTreatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) studyCirculation2007116218018717576867
   PubMed Web of Science ®Google Scholar
• MueckWLensingAWAgnelliGDécoususHPrandoniPMisselwitzFRivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke preventionClin Pharmacokinet2011501067568621895039
   PubMed Web of Science ®Google Scholar
• ROCKET AF Study InvestigatorsRivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF studyAm Heart J2010159334034720211293
   PubMed Web of Science ®Google Scholar
• WongKSHuDYOommanARivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trialStroke Epub4242014
   Google Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA2001285222864287011401607
   PubMed Web of Science ®Google Scholar
• LipGYHNieuwlaatRPistersRLaneDCrijnsHRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on Atrial FibrillationChest2010137226327219762550
   PubMed Web of Science ®Google Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar
• TurpieAGSchmidtACKreutzRRationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgeryVasc Health Risk Manag2012836337022701330
   PubMedGoogle Scholar
• TurpieAGHaasSKreutzRA non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustmentThromb Haemost201411119410224154549
   PubMed Web of Science ®Google Scholar
• KakkarAKMuellerIBassandJPInternational longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)Am Heart J20121631131922172431
   PubMed Web of Science ®Google Scholar
• PicciniJPFrauloESAnsellJEOutcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AFAm Heart J2011162460661221982650
   PubMed Web of Science ®Google Scholar